Basis: FMP quote price / unrounded diluted EPS from four consecutive issuer fiscal quarters. Source: stored company filings and market data; unavailable inputs remain N/A.
The P/E ratio is N/A as of 2026-10-06T16:35:27.385Z.
Calculation as of: 2026-10-06T16:35:27.385Z.
Quote observation: 2026-10-06T16:30:58.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: a4d4a138dd8434a7100af030d95cbc2d10a06a8c2908319c26333cf652cdf112
PE RATIO
N/A
Market Cap
$3.24M
PE Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$3.35M
PE Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | PE RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Aethlon Medical, Inc. (AEMD) | $3.29M | N/A | N/A | N/A | N/A |
| Paranovus Entertainment Technology Ltd. (PAVS)vs › | $3.24M | N/A | N/A | N/A | N/A |
| Cadrenal Therapeutics, Inc. Common Stock (CVKD)vs › | $3.35M | N/A | N/A | N/A | N/A |
| Moolec Science S.A. (MLEC)vs › | $3.47M | N/A | N/A | N/A | N/A |
| IceCure Medical Ltd (ICCM)vs › | $3.13M | N/A | N/A | N/A | N/A |
| MBody AI Ltd. (MBAI)vs › | $3.18M | N/A | N/A | N/A | N/A |
| Eocene Ltd. (EOCN)vs › | $3.46M | N/A | N/A | N/A | N/A |
| Adagio Medical Holdings, Inc. (ADGM)vs › | $3.13M | N/A | N/A | N/A | N/A |
| Evogene Ltd. (EVGN)vs › | $3.46M | N/A | N/A | N/A | N/A |
| Revelation Biosciences, Inc. (REVB)vs › | $3.10M | N/A | 0.90 | 0.90 | 0.90 |
Trailing P/E
N/A
Forward P/E
N/A
Forward P/E is calculated using analyst consensus EPS estimates for the current or next fiscal year.
Calculation:
Current Price
$6.25
Forward EPS (Est.)
$-6.49
Forward P/E
N/A
Source: FMP Analyst Consensus Estimates. Forward EPS represents the average analyst estimate for the nearest fiscal year.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
